Abstract:Phosphatidylinositol (PtdIns) 3-kinase is an enzyme implicated in growth factor signal transduction by associating with receptor and nonreceptor tyrosine kinases, including the platelet-derived growth factor receptor. Inhibitors of PtdIns 3-kinase could potentially give a better understanding of the function and regulatory mechanisms of the enzyme. Quercetin, a naturally occurring bioflavinoid, was previously shown to inhibit PtdIns 3-kinase with an IC50 of 1.3 microgram/ml (3.8 microM); inhibition appeared to be directed at the ATP-binding site of the kinase. Analogs of quercetin were investigated as PtdIns 3-kinase inhibitors, with the most potent ones exhibiting IC50 values in the range of 1.7-8.4 micrograms/ml. In contrast, genistein, a potent tyrosine kinase inhibitor of the isoflavone class, did not inhibit PtdIns 3-kinase significantly (IC50 > 30 micrograms/ml). Since quercetin has also been shown to inhibit other PtdIns and protein kinases, other chromones were evaluated as inhibitors of PtdIns 3-kinase without affecting PtdIns 4-kinase or selected protein kinases. One such compound, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (also known as 2-(4-morpholinyl)-8-phenylchromone, LY294002), completely and specifically abolished PtdIns 3-kinase activity (IC50 = 0.43 microgram/ml; 1.40 microM) but did not inhibit PtdIns 4-kinase or tested protein and lipid kinases. Analogs of LY294002 demonstrated a very selective structure-activity relationship, with slight changes in structure causing marked decreases in inhibition. LY294002 was shown to completely abolish PtdIns 3-kinase activity in fMet-Leu-Phe-stimulated human neutrophils, as well as inhibit proliferation of smooth muscle cells in cultured rabbit aortic segments. Since PtdIns 3-kinase appears to be centrally involved with growth factor signal transduction, the development of specific inhibitors against the kinase may be beneficial in the treatment of proliferative diseases as well as in elucidating the biological role of the kinase in cellular proliferation and growth factor response.

LY294002 Inhibits Leukemia Cell Invasion and Migration Through Early Growth Response Gene 1 Induction Independent of Phosphatidylinositol 3-Kinase-akt Pathway.

A PI3K inhibitor-induced growth inhibition of cancer cells is linked to MEK-ERK pathway

Erianin Suppresses the Development of Acute Myeloid Leukemia Via PPARɑ and Regulating PI3K/AKT Signaling Pathways

Combination of RSK Inhibitor LJH-685 and FLT3 Inhibitor FF-10101 Promoted Apoptosis and Proliferation Inhibition of AML Cell Lines

Cytotoxic activity of lithospermum erythrorhizon root extract against childhood acute leukemia cells via regulation of PI3K/AKT/mTOR pathway

Polyphyllin I Induces Cell Cycle Arrest and Apoptosis in Human Myeloma Cells Via Modulating Β‐catenin Signaling Pathway

A novel iheyamine A derivative L42 suppresses acute myeloid leukemia via dual regulation of the PI3K/AKT/FOXO3a axis and TNF signaling pathway

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia

Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways

Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).

A Pyridinesulfonamide Derivative FD268 Suppresses Cell Proliferation and Induces Apoptosis Via Inhibiting PI3K Pathway in Acute Myeloid Leukemia

A natural acylphloroglucinol triggered antiproliferative possessions in HEL cells by impeding STAT3 signaling and attenuating angiogenesis in transgenic zebrafish model

Dual PI3K/mTOR inhibitor NVP‐BEZ235 decreases the proliferation of doxorubicin‐resistant K562 cells

LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway

The role of leucine-rich alpha-2-glycoprotein-1 in proliferation, migration, and invasion of tumors

LJNK, an indoline-2,3-dione-based aminopeptidase N inhibitor with promising antitumor potency.

LL1, a Novel and Highly Selective STAT3 Inhibitor, Displays Anti‐colorectal Cancer Activities in Vitro and in Vivo

Response and determinants of cancer cell susceptibility to PI3K inhibitors

Targeting PI3K Signaling in Acute Lymphoblastic Leukemia

The effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on Immune Evasion Mechanisms of Acute Myeloid Leukemia Cell Line